RASSF1A Enhances Chemosensitivity of NSCLC Cells Through Activating Autophagy by Regulating MAP1S to Inactivate Keap1-Nrf2 Pathway

OBJECTIVE: Cisplatin (DDP) is an effective first-line therapy for non-small cell lung cancer (NSCLC) treatment; however, it can cause resistance and thus pose an obstacle to the efficacy of chemotherapy in NSCLC. This study aims to detect the effect of RASSF1A on DDP resistance of NSCLC and the unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jincai, Zhang, Xufeng, Yang, Fang, Yang, Yuguang, Wang, Tianjiao, Liu, Wenming, Zhou, Hongfeng, Zhao, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797300/
https://www.ncbi.nlm.nih.gov/pubmed/33442234
http://dx.doi.org/10.2147/DDDT.S269277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797300/
https://www.ncbi.nlm.nih.gov/pubmed/33442234
http://dx.doi.org/10.2147/DDDT.S269277

Ejemplares similares